Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Doxorubicin Market
Doxorubicin Market Size
- Report ID: GMI11168
- Published Date: Sep 2024
- Report Format: PDF
Doxorubicin Market Size
Doxorubicin Market size was valued at around USD 1.3 billion in 2023 and is estimated to grow at a 6.3% CAGR from 2024 to 2032. Doxorubicin, an anthracycline-derived chemotherapy drug from the bacterium Streptomyces Peucetian, is primarily employed in the treatment of various cancer types. By disrupting the DNA within cancer cells, doxorubicin halts their growth and division, ultimately inducing cell death.
The rising incidence of cancer is a crucial factor driving market growth. For instance, according to the World Health Organization (WHO), in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths worldwide. This underscores the growing demand for effective chemotherapy agents such as doxorubicin, as the increasing burden of cancer necessitates advanced and widely used treatment options to manage and combat the disease.
| Report Attribute | Details |
|---|---|
| Base Year: | 2023 |
| Doxorubicin Market Size in 2023: | USD 1.3 Billion |
| Forecast Period: | 2024 to 2032 |
| Forecast Period 2024 to 2032 CAGR: | 6.3% |
| 2032 Value Projection: | USD 2.2 Billion |
| Historical Data for: | 2021-2023 |
| No. of Pages: | 152 |
| Tables, Charts & Figures: | 225 |
| Segments covered: | Drug Formulation, Application, Distribution Channel, and Region |
| Growth Drivers: |
|
| Pitfalls & Challenges: |
|
Additionally, advancements in chemotherapy treatments, a growing focus on personalized medicine, and increased government funding for cancer research are also key factors contributing to revenue growth in the market.
Frequently Asked Questions (FAQ) :
Doxorubicin Market Scope
